The Aporia · Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read the original at Toronto Star ↗

Cite

APA MLA Chicago

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). (2026, October 2). Toronto Star. https://www.thestar.com/globenewswire/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_555e4d1e-351b-5011-84f5-d310f559bd96.html

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Quick Summary

Xenon Pharmaceuticals announced on October 2, 2026, that it had granted equity inducements to eight new non-officer employees, including 17,850 share options and 10,500 restricted share units (RSUs). The total grants were valued at the closing stock price of $38.93 per common share on October 1, 2026. The article details the vesting schedules for both share options and RSUs over a four-year period, contingent upon continued employment with Xenon.

Written by AI on 2026-10-03, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company listed on Nasdaq as XENE, announced equity inducement grants to eight new non-officer employees on October 1, 2026. The grants consist of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs), approved by the company's Compensation Committee. The share options have an exercise price of $38.93 per common share, matching the closing stock price on the grant date. The RSUs will vest as to 25% of the underlying shares annually over four years starting from October 1, 2026, contingent upon continued employment with Xenon Pharmaceuticals.

Written for “Xenon Pharmaceuticals Grants” on 2026-10-31, grounded in this article and the 0 other(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Signals How these are calculated →

Claims extracted

sentences that state something as happening or true

Uncertain

0 of 7 hedged ("reportedly", "may", "according to")

Leaning

not political

takes no side on a contested political question

Publisher signals

64/100

Toronto Star's corrections and hedging, across everything collected from it. Not a measure of accuracy.

Outlets on this story

Health

Same framing elsewhere

articles that frame the event the way this one does

Publisher

Claims (7 extracted, 0 hedged)

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). asserted

Inc. → focus → options

All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). asserted

All → forego → Rule

The share options have an exercise price of $38.93 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of October 1, 2026. asserted

which → have → October

The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. asserted

% → vest → Company

Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. asserted

option → have → Plan

The RSUs will vest as to 25% of the underlying shares on each of the first four anniversaries of the grant date of October 1, 2026, subject to such employee’s continued service relationship with the Company. asserted

RSUs → vest → Company

Each RSU grant is subject to the terms and conditions of the restricted share unit award agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. asserted

grant → restate → Plan

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quick Summary

AI analysis

Story

Compared with similar articles

Signals How these are calculated →

How this is being covered How these are calculated →

Publisher

Who wrote this

Topics

Subjects

Narrative

Claims (7 extracted, 0 hedged)